Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-program...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Marc, Chepeha, Douglas, Araujo, Daniel V, Diaz-Mejia, J. Javier, Olson, Peter, Prawira, Amy, Spreafico, Anna, Bratman, Scott V, Shek, Tina, de Almeida, John, R Hansen, Aaron, Hope, Andrew, Goldstein, David, Weinreb, Ilan, Smith, Stephen, Perez-Ordoñez, Bayardo, Irish, Jonathan, Torti, Dax, Bruce, Jeffrey P., Wang, Ben X., Fortuna, Anthony, Pugh, Trevor J., Der-Torossian, Hirak, Shazer, Ronald, Attanasio, Nickolas, Au, Qingyan, Tin, Antony, Feeney, Jordan, Sethi, Himanshu, Aleshin, Alexey, Chen, Isan, Siu, Lillian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488751/
https://www.ncbi.nlm.nih.gov/pubmed/34599023
http://dx.doi.org/10.1136/jitc-2021-003476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488751/
https://www.ncbi.nlm.nih.gov/pubmed/34599023
http://dx.doi.org/10.1136/jitc-2021-003476

Ejemplares similares